Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

pasireotide × Gynecologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 13 Gastrointestinal 9 NET 7 Genitourinary 4 Thoracic 2 Lymphoid 2 Dermatologic 2 Breast 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Head & Neck 1 Gynecologic 1 CNS 1

Conditions

Peritoneal Neoplasms 1

Interventions

Paclitaxel 486 Carboplatin 445 Cisplatin 288 Bevacizumab 210 pembrolizumab 188 Gemcitabine 122 olaparib 111 Cyclophosphamide 110 liposomal doxorubicin 103 Topotecan 102 Radiotherapy 99 Taxes 87 Brachytherapy 81 Docetaxel 80 Drug Therapy 76 niraparib 73 Doxorubicin 72 Surveys and Questionnaires 70 Magnetic Resonance Spectroscopy 63 Nivolumab 61 Specimen Handling 59 Blood Specimen Collection 57 Biopsy 55 Hyperthermic Intraperitoneal Chemotherapy 53 fludarabine 51 Filgrastim 43 durvalumab 40 Letrozole 40 Surgical Procedures, Operative 38 Platinum 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04826432 2024-02-08

PASIREOCHIP

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Terminated

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡